Video Series

Experts discuss how arrhythmia evaluation is tailored based on symptom frequency, severity, and patient risk, using a stepwise approach from short-term to extended monitoring to guide timely and effective diagnosis and management.

Experts discuss how rising arrhythmia burdens and workforce challenges are driving a shift toward team-based care, smarter diagnostics, and artificial intelligence–driven risk stratification to improve outcomes and efficiency.

Panelists discuss the critical role of effective follow-up and multidisciplinary care in managing hidradenitis suppurativa, emphasizing ongoing patient education, coordinated referrals, and personalized treatment plans to improve adherence and long-term outcomes.

Panelists discuss the importance of clear communication, financial support, and leveraging telehealth and peer networks to improve equitable access and adherence to specialized care and treatment for underserved patients with hidradenitis suppurativa.

Panelists discuss how atopic dermatitis (AD) presents differently across skin tones, appearing as purple, gray, or barely visible inflammation rather than classic redness, with perifollicular prominence and postinflammatory pigmentation changes being more prominent in patients with darker skin.

Panelists discuss how atopic dermatitis (AD) extends far beyond pruritus to include pain, sleep disturbances, psychosocial stigma, and quality-of-life impacts that affect patients’ work, school, and daily functioning regardless of disease severity.

Panelists discuss how switching therapies in patients with alopecia areata (AA) is often necessary when initial treatments fail, though it can create a cost burden, and how beyond updated guidelines, there are unmet needs such as improved long-term treatments and better psychological support for patients.

Panelists discuss how the high failure rate of conventional treatments for long-standing, extensive alopecia areata (AA) may be due to factors such as disease chronicity and inadequate response to available therapies, and the need for key updates in AA management guidelines, which have not been revised since 2003.

Experts discuss the persistent clinical and systemic challenges in diagnosing and treating atrial fibrillation, emphasizing the need for earlier identification—especially in high-risk, comorbid populations—while highlighting the limitations of current risk models, the complexity of managing atrial fibrillation burden, and the importance of integrating wearable data into precision-based care without overburdening clinicians or compromising clinical relevance.

Experts discuss the multifaceted management of atrial fibrillation, stressing the importance of addressing comorbid conditions alongside the arrhythmia itself, while highlighting the challenges of underdiagnosis, the rise of subclinical cases detected through wearable technology, and the need to align emerging diagnostic tools with evidence-based care to avoid unnecessary interventions and optimize outcomes.

Panelists discuss the challenges of biologic access in hidradenitis suppurativa due to utilization management policies like step therapy, emphasizing the need for patient education, strategic planning, and leveraging resources—including clinical trials—to improve timely treatment and outcomes.

Panelists discuss the anticipated 2026 updates to the American Academy of Dermatology guidelines for hidradenitis suppurativa, highlighting efforts to unify treatment protocols, support biologic access, and accommodate emerging therapies within a rapidly evolving therapeutic landscape.

Panelists discuss how health care professionals face educational gaps in understanding atopic dermatitis (AD) immunopathogenesis, with advanced practice providers (APPS) particularly needing additional training outside standard curricula to master biologic therapy selection.

An expert discusses the rapidly evolving landscape of ITP treatments, highlighting emerging therapies such as Bruton’s tyrosine kinase inhibitors, neonatal Fc receptor antagonists, anti-CD38 antibodies, and innovative approaches like CAR T-cell therapy that offer new hope for improved patient outcomes.

Panelists discuss how atopic dermatitis involves complex inflammatory and neuronal pathways, with IL-4, IL-13, and IL-31 cytokines driving Th2-mediated inflammation that varies across different racial populations.

An expert discusses the expanded treatment options for refractory ITP, emphasizing accurate diagnosis, combination therapies targeting platelet production and destruction, and the evolving role of splenectomy with improved safety measures.

Lauren Wisk, PhD, discusses the implications of an all-inclusive long COVID definition and its application in clinical practices.

Panelists discuss how adverse events associated with conventional therapies for alopecia areata (AA) are monitored through regular patient assessments, and how these events are managed by adjusting treatment or providing supportive care as needed.

Panelists discuss how adherence to conventional therapies for alopecia areata (AA) can be challenging, with adverse effects often impacting patient compliance, and how the most common cause of nonadherence is the lack of visible improvement or perceived efficacy.

The American Journal of Managed Care spoke with Lauren Wisk, PhD, about her recent study aimed at assessing various definitions of long COVID and how a standard definition might aid physicians in clinical practices.

Experts discuss the complex clinical and economic challenges of atrial fibrillation, emphasizing the need for personalized care that balances symptom management, stroke prevention, and risk factor control—while recent evidence on subclinical atrial fibrillation highlights the limitations of widespread anticoagulation, reinforcing the importance of targeted, value-based strategies for optimal outcomes.

Experts discuss the growing role of early detection and predictive strategies in managing arrhythmias—particularly atrial fibrillation—highlighting the impact of wearable technology, challenges in diagnosis due to intermittent symptoms, and the shift toward more personalized, value-based care driven by timely evaluation and evidence-based interventions.

Panelists discuss the critical importance of early biologic therapy initiation in hidradenitis suppurativa to prevent irreversible tissue damage, reduce disease burden, and overcome socioeconomic and systemic barriers that delay timely treatment and worsen patient outcomes.

Panelists discuss the challenges and evolving landscape of step therapy protocols in hidradenitis suppurativa treatment, emphasizing the impact on patient adherence, the potential benefits of earlier biologic use, and the need for advocacy to improve access and outcomes.

Panelists discuss how providers and payers must collaborate to develop innovative coverage criteria for BTK inhibitors that prevent patients with subclinical progression from being forced to fail multiple inappropriate therapies before accessing optimal treatment.

An expert discusses how ITP treatment success is monitored through maintaining safe platelet levels and symptom control, managing relapses, and tailoring follow-up based on therapy type and patient needs.

An expert discusses the importance of balancing efficacy with safety in ITP treatment, emphasizing cautious use of steroids, close monitoring of therapy-related side effects, and maintaining platelet counts just above bleeding thresholds to minimize long-term drug toxicity through personalized, informed care.

Panelists discuss how key factors such as disease severity, patient preference, and payer requirements influence the choice of initial therapy for alopecia areata (AA), highlighting which drug classes have the highest and lowest success rates.

Panelists discuss how the decision to treat vs observe alopecia areata (AA) depends on factors such as disease severity, patient symptoms, and the use of scoring systems to guide treatment decisions.

Panelists discuss how upcoming ASCO presentations will focus on long-term CAR T-cell therapy outcomes showing potential cure plateaus, minimal residual disease (MRD)–guided treatment escalation/de-escalation strategies, tri-specific antibodies, and the economic value of using MRD negativity to guide maintenance therapy discontinuation decisions.